%20Ver-2.png)
Autoimmune diseases are often treated with lifelong immunosuppression that manages symptoms without correcting underlying immune dysfunction.
Emerging evidence suggests that selectively removing pathogenic immune cell populations can enable durable remission by restoring immune balance. Liberate’s autoimmune programs are built around this principle.
B-Cell–Driven Autoimmune Disease
Liberate is developing therapies targeting CD19 to address autoimmune diseases driven by pathogenic B cells, including:
• Systemic Sclerosis
• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• Myasthenia Gravis
By enabling genetic medicines to reach immune cells in relevant tissues, this approach aims to reset dysregulated immune responses without chronic, non-specific suppression.
